Morgan Stanley initiated coverage of Aardvark Therapeutics (AARD) with an Overweight rating and $29 price target The firm believes the Phase 2 data support the potential of ARD-101 in Prader-Willie syndrome, which represents a blockbuster opportunity. It expects positive Phase 3 data in early 2026 to drive meaningful upside in the shares. Aardvark has a differentiated approach to treating metabolic disorders associated with hunger, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD: